ProBioGen’s growth strategy continues successfully

Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team

Dr. Reddy's Laboratories to acquire Mayne Pharma’s U.S. generic prescription product portfolio

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.

NATCO launches generic Pomalidomide Capsules in Canada

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules

Alembic gets USFDA final approval for ANDA Docetaxel Injection

CarDekho adds Medulance to provide emergency medical services

Granules India gets USFDA approval for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months

Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine

The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability